drugset

drugset / Trial / NCT00635700

Ziprasidone in the Psychosis Prodrome

NCT00635700 ↗

Phase 2 Completed 51 enrolled Yale University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Timeline

Start: 2008-03
Primary completion: 2012-11
Completion: 2012-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ziprasidone	Small molecule	—	—

Indications